Medicinal uses of dihydropyrazoles

Details Medicinal uses of dihydropyrazoles Medicinal uses of dihydropyrazoles

2005-04-12

2005-04-12

Chang, Ceila (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S275400, C514S341000

Reexamination Certificate

active

06878729

ABSTRACT:
Compounds having a structure according to Formula (I):are effective in a method of increasing erythropoietin and vascularization of tissue in a subject in need thereof.

REFERENCES:
patent: 3947583 (1976-03-01), Berenson
patent: 4997835 (1991-03-01), Schaper et al.
patent: 5073492 (1991-12-01), Chen et al.
patent: 5084458 (1992-01-01), Schaper et al.
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5219739 (1993-06-01), Tischer et al.
patent: 5283341 (1994-02-01), Tanaka et al.
patent: 5882914 (1999-03-01), Semenza
patent: 5985913 (1999-11-01), Williams et al.
patent: 6020462 (2000-02-01), Semenza
patent: 6291505 (2001-09-01), Huebner et al.
patent: 19904391 (2000-08-01), None
patent: WO 9219615 (1992-11-01), None
patent: WO 9856377 (1998-12-01), None
patent: WO 9958523 (1999-11-01), None
patent: WO 9962884 (1999-12-01), None
patent: WO 0010578 (2000-03-01), None
patent: WO 0045894 (2000-08-01), None
patent: WO 0076503 (2000-12-01), None
Bun et al., “Oxygen Sensing and Molecular Adaptation of Hypoxia”,Amer. Physiological Society, 1996, pp. 839-885, vol. 76, No. 3.
Semenza, “Regulation of Mammalian O2Homeostasis by Hypoxia-Inducible Factor 1.”,Annu. Rev. Cell Dev. Biol., 1999, pp. 551-578, vol. 15.
Shweiki et al., “Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: Implications for tumor angiogenesis”,Proc. Natl. Acad. Sci., 1995, pp. 768-772, vol. 92.
Semenza, “HIF-1: mediator of physiological and pathophysiological responses to hypoxia”,J. Appl. Physiol., 2000, pp. 1474-1480, vol. 88.
Semenza, “Hypoxia-inducible factor 1: master regulator of O2homeostasis”,Genetics&Development, 1998, pp. 588-594, vol. 8.
Jiang et al., “Transactivation and inhibitory domanins of hypoxia-inducible facter 1α”,J. Biol. Chem., 1997, pp. 19253-19260, vol. 272, No. 31.
Jiang et al., “Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1”,J. of Biol. Chem., 1996, pp. 17771-17778, vol. 271, No. 30.
Pearlman et al., “Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis”,Nature Medicine, 1995, pp. 1085-1089, vol. 1, No. 10.
Takeshita et al., “A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model”,J. Clin. Invest., 1994, pp. 662-670, vol. 93.
Hendel et al., “Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion”,Circulation, 2000, pp. 118-121, vol. 101, No. 2.
Schwartz et al., “Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction mdoel in the rat—angiogenesis and angioma formation”,J. Amer. College of Cardiology, 2000, pp. 1323-1330, vol. 35, No. 5.
Shweiki et al., “Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis”,Letters to Nature, 1992, pp. 843-845, vol. 359.
Levy et al., “Transcriptional regulation of the rat vascular endothelial growth facror gene by hypoxia”,Drug Disc. Today, 1995, pp. 13333-13340, vol. 270, No. 22.
Ikeda et al., “Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells”,J. Biol. Chem., 1995, pp. 19761-19766, vol. 270, No. 34.
Levy et al., “Post-transcriptional regulation of vascular endothelial growth factor by hypoxia”,Drug Disc Today, 1996, pp. 2746-2753, vol. 271, No. 5.
Agani et al., “Mersalyl is a novel inducer of vascular endothelial growth factor gene expression and hypoxia-inducible factor 1 activity”,Mol. Pharmacol., 1998, pp. 749-754, vol. 54.
Brogi et al., “Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only”,Circulation, 1994, pp. 649-652, vol. 90.
Van Belle et al., “Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor”,Circulation, 1998, pp. 381-390, vol. 97. No. 4.
Semenza, “Regulation of erythropoietin production”,Hematol. Oncol., Clin. N. Amer., 1994, pp. 863-885, vol. 8, No. 5.
Semenza et al., “Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1”,J. Biol. Chem., 1994, pp. 23757-23763, vol. 269, No. 38.
Kranz, “Blood”,J. of Amer. Society of Hematology, 1991, pp. 419-434, vol. 77, No. 3.
Quroshi et al., “Minicry of erythropoietin by a nonpeptide molecule”,PNAS, 1999, pp. 12156-12161, vol. 96, No. 21.
Manna et al., “Inhibitory Effect of 1,3,5-Triphenyl-4,-5-Dihydro-(1H)-Pyrazole Derivatives on Activity of Amine Oxidases”,J. Enzyme Inhibition, 1998, pp. 207-216, vol. 13.
Rao et al., “Synthesis and ANTIMICROBIAL Activity of Some New 1,8-NAPH-Thyridines”,Indian J. of Heterocyclic Chem., 1995, pp. 211-214, vol. 4.
Bilgin et al., “Some 1,3,5-Triphenyl-2-Pyrazolines with Antidepressant Activities”,Database CA online, Chemical Abstracts Service, Columbus, Ohio, US, Accession No. 120:235419 XP002206884, Abstract.

Affiliated with

Also associated with

Rating

Medicinal uses of dihydropyrazoles does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Medicinal uses of dihydropyrazoles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medicinal uses of dihydropyrazoles will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3378297